On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...
The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
4h
A trio of environmental scientists at the Chinese Academy of Sciences, Institute of Geographic Sciences and Natural Resources ...
Fintel on MSN2d
Maxim Group Downgrades Gilead Sciences (GILD)Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...
TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...
Hosted on MSN4d
Gilead Sciences Earnings Transcript (NASDAQ:GILD)Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca. Just after market closed today, we ...
Joseph Stringer’s rating is based on a combination of factors including Gilead Sciences’ recent financial performance and future growth potential. The company reported strong third-quarter results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback